CJC-1295 (no-DAC) + Ipamorelin Blend — Research Consultation
A combined-blend research preparation of CJC-1295 without DAC (a tetra-substituted GHRH(1-29) analogue) and Ipamorelin (a selective ghrelin-receptor agonist). Published research describes the additive growth-hormone-release effect produced by simultaneous GHRH-receptor and ghrelin-receptor activation.
What this blend is
The combined research preparation pairs CJC-1295 (no-DAC) — a stabilised GHRH(1-29) analogue with four amino-acid substitutions for protease resistance — with Ipamorelin, a five-amino-acid selective ghrelin-receptor agonist. The two compounds act on different receptors and produce additive growth-hormone release in published pharmacology research.
GHRH + GHRP — combined-signalling research model
GHRH analogues bind the GHRH receptor on somatotroph cells. GHRPs bind the ghrelin (GHS-R1a) receptor on the same cells. Published research shows that simultaneous activation of both receptor pathways produces a larger GH pulse than either alone — the basis for the combined-signalling research model used in many human pharmacology studies.
CJC-1295 with DAC vs. without DAC
The DAC (Drug Affinity Complex) variant of CJC-1295 has a maleimido-propionic-acid tag that covalently binds serum albumin, producing a longer half-life. The no-DAC variant retains the four stabilising substitutions without the albumin tag, giving a shorter pharmacokinetic profile that more closely matches Ipamorelin's. Researchers studying combined GHRH + GHRP pharmacology typically use the no-DAC variant.
Quality verification
Lyophilised blend manufactured under ICH Q7 GMP standards. Independent HPLC verification at a US-based third-party laboratory confirms peak-area purity of both peptides individually. COA available through the in-chat consultation.
Common research questions
- Is the CJC-1295 + Ipamorelin blend legal in the UAE?
- Both peptides are classified as research compounds in the UAE and are sold through standard wellness-supply channels with VAT compliance applied to every dispatch.
- What dose ranges does the published research describe?
- Published pharmacology research and grey-research protocols commonly describe 100-300 mcg of each peptide per administration, two-to-three times daily, in cycles of 8-12 weeks followed by a rest period. The blend formulation allows both peptides to be drawn in a single injection.
- Why no-DAC instead of with-DAC?
- No-DAC matches Ipamorelin's pharmacokinetic profile, so both peptides act within the same time window. The with-DAC variant lasts much longer (5-10 days), which is incompatible with the pulsatile GH-release research model the blend is designed for.
- Why pair instead of separate?
- GHRH analogues and GHRPs act on different receptors and produce additive GH release in the published literature. The paired protocol is the standard combined-signalling research model. The blend simplifies administration relative to drawing two compounds separately.
- How is purity verified?
- HPLC peak-area purity (≥98%) at a US-based third-party laboratory for both peptides. COA available through the chat.
- Shelf life and storage?
- Lyophilised powder is ambient-temperature stable in transit; -20°C long-term storage; refrigerated post-reconstitution per the supplied protocol.
- How fast is delivery in the UAE?
- Same-day delivery within Dubai, next-business-day across the rest of the UAE.
Peer-reviewed references
Related consultations
Further reading
Talk to Nour about your research protocol
Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.